Cover Image
市場調查報告書

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6) :開發中產品分析

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363572
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6) :開發中產品分析 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 110 Pages
簡介

本報告提供組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的概要

治療藥的開發

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各開發階段

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各治療範圍

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各適應症

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):企業開發中的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):大學/機關開發中的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的治療藥的開發企業

  • Acetylon Pharmaceuticals, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • HitGen LTD
  • Kancera AB
  • Karus Therapeutics Limited
  • Lycera Corp.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • OncoHoldings, Inc.
  • Quimatryx, S.L.
  • Sigma-Tau S.p.A.
  • SK Biopharmaceuticals Co., Ltd.
  • 武田藥品工業
  • TetraLogic Pharmaceuticals

藥物簡介

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):暫停中的計劃

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0109TDB

Summary

Global Markets Direct's, 'Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016', provides in depth analysis on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Overview
  • Therapeutics Development
    • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Stage of Development
    • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Therapy Area
    • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Indication
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Companies
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Universities/Institutes
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    • Acetylon Pharmaceuticals, Inc.
    • Chong Kun Dang Pharmaceutical Corp.
    • HitGen LTD
    • Kancera AB
    • Karus Therapeutics Limited
    • Lycera Corp.
    • Merck & Co., Inc.
    • Millennium Pharmaceuticals, Inc.
    • OncoHoldings, Inc.
    • Quimatryx, S.L.
    • Sigma-Tau S.p.A.
    • SK Biopharmaceuticals Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • TetraLogic Pharmaceuticals
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
    • ACY-241 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-738 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-775 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-1A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit HDAC6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HG-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IKH-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KA-2507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAN-0439221 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAN-439782 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAR-3000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • N-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONCO-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QTX-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QTX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QTX-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ricolinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-3595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Projects
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Featured News & Press Releases
    • Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models
    • Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology
    • Dec 07, 2015: Acetylon Presents Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma
    • Dec 07, 2015: Acetylon Presents Data on the use of HDAC 6 Inhibitors Ricolinostat and ACY-241 in Combination with Pomalidomide for the Treatment of Multiple Myeloma
    • Nov 06, 2015: Acetylon's Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-tumor Activity of Paclitaxel in Preclinical Solid Tumor Models
    • Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
    • Jun 15, 2015: Acetylon Pharmaceuticals Presented Positive Preliminary Data from Phase 1b/2 Trial of Ricolinostat in Combination with Pomalyst as Potential Oral Treatment for Patients with Multiple Myeloma
    • Apr 22, 2015: Acetylon Presents Data on Synergistic Activity of Selective HDAC6 Inhibition in Preclinical Models of Multiple Myeloma and Mantle Cell Lymphoma at the American Association for Cancer Research Annual Meeting
    • Jan 21, 2015: Acetylon Presents at the Wells Fargo Celgene Partnership Forum
    • Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
    • Dec 09, 2014: Acetylon Pharmaceuticals Announces Ricolinostat Continues to Demonstrate Clinically Meaningful and Durable Disease Response Rates in Phase 1b Combination Studies in Multiple Myeloma
    • Dec 04, 2014: Acetylon Pharmaceuticals Initiates Phase 2 Study of Ricolinostat (ACY-1215) in Combination with Pomalyst
    • Dec 01, 2014: Acetylon's Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition
    • Jun 13, 2014: Acetylon Pharmaceuticals Reports Ricolinostat (ACY-1215) is Active and Well-tolerated in Ongoing Phase 1b Studies in Patients with Refractory Multiple Myeloma at the 19th Congress of the EHA
    • May 28, 2014: TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Pipeline by HitGen LTD, H1 2016
  • Pipeline by Kancera AB, H1 2016
  • Pipeline by Karus Therapeutics Limited, H1 2016
  • Pipeline by Lycera Corp., H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Pipeline by OncoHoldings, Inc., H1 2016
  • Pipeline by Quimatryx, S.L., H1 2016
  • Pipeline by Sigma-Tau S.p.A., H1 2016
  • Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top